Prakash Diwan of Altamount Capital Management is of the view that one may look at Sun Pharma.
Prakash Diwan of Altamount Capital Management told CNBC-TV18, "Sun Pharma - eventually when people gave up on this expectation of the USFDA visit at Halol in the month of December and it was actually the Australian government regulators that did the entire exercise and apparently gave out a very positive outcome to the unit. I think the market is kind of now sensing some sort of reasonable valuations that they would have to start looking for given the kind of levels we are at and in pharma seems be an obvious kind of a this thing, but my sense is it will probably be only the larger ones like Sun Pharma, Cipla which could kind of work well with confidence that you have.”
“Otherwise the smaller players could still struggle for a couple of quarters in the pharma revival. But Sun Pharma we are extremely positive even at these levels it does offer a tactical and a long term potential to move up," he added.